Targeting impulsivity in Parkinson’s disease using atomoxetine
In a double-blind randomized placebo-controlled study, Kehagia et al. investigate the effects of a single dose of atomoxetine, a selective noradrenaline reuptake inhibitor, in 25 patients with Parkinson’s disease. Consistent with the presence of a longstanding noradrenergic deficit, atomoxetine impr...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Oxford University Press
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065022/ |